Cargando…

Stratified Medicine and Reimbursement Issues

Stratified Medicine (SM) has the potential to target patient populations who will most benefit from a therapy while reducing unnecessary health interventions associated with side effects. The link between clinical biomarkers/diagnostics and therapies provides new opportunities for value creation to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fugel, Hans-Joerg, Nuijten, Mark, Postma, Maarten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2012
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3471319/ https://www.ncbi.nlm.nih.gov/pubmed/23087645 http://dx.doi.org/10.3389/fphar.2012.00181

Ejemplares similares

Economic Evaluation in Stratified Medicine: Methodological Issues and Challenges
por: Fugel, Hans-Joerg, et al.
Publicado: (2016)

An economic assessment of embryo diagnostics (Dx) - the costs of introducing non-invasive embryo diagnostics into IVF standard treatment practices
por: Fugel, Hans-Joerg, et al.
Publicado: (2014)

Cost-Utility Analysis: Current Methodological Issues and Future Perspectives
por: Nuijten, Mark J. C., et al.
Publicado: (2011)

The Impact of Reimbursement Practices on the Pharmaceutical Market for Off-Patent Medicines in Slovakia
por: Tesar, Tomas, et al.
Publicado: (2021)

Application of Economic Evaluation to Assess Feasibility for Reimbursement of Genomic Testing as Part of Personalized Medicine Interventions
por: Simeonidis, Stavros, et al.
Publicado: (2019)

Use of medicine pricing and reimbursement policies for universal health coverage in Indonesia
por: Wasir, Riswandy, et al.
Publicado: (2019)

How Changes in Reimbursement Practices Influence the Financial Sustainability of Medicine Policy: Lessons Learned from Slovakia
por: Tesar, Tomas, et al.
Publicado: (2019)

Critical Appraisal of Reimbursement List in Bosnia and Herzegovina
por: Mujkic, Sabina, et al.
Publicado: (2017)

Critical Reflections on Reimbursement and Access of Advanced Therapies
por: Simoens, Steven, et al.
Publicado: (2022)

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries
por: Kawalec, Paweł, et al.
Publicado: (2017)

The implementation of HTA in medicine pricing and reimbursement policies in Indonesia: Insights from multiple stakeholders
por: Wasir, Riswandy, et al.
Publicado: (2019)

Orphan drugs’ clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement
por: Eichler, Hans-Georg, et al.
Publicado: (2023)

Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
por: Stawowczyk, Ewa, et al.
Publicado: (2019)

Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2018)

Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans
por: Salek, Sam, et al.
Publicado: (2019)

Reimbursement decision-making system in Poland systematically compared to other countries
por: Mela, Aneta, et al.
Publicado: (2023)

Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2019)

A Comparison of Reimbursement Recommendations by European HTA Agencies: Is There Opportunity for Further Alignment?
por: Allen, Nicola, et al.
Publicado: (2017)

Assessing the Accuracy of Sales Forecasts Submitted by Pharmaceutical Companies Applying for Reimbursement in Austria
por: Kossmeier, Michael, et al.
Publicado: (2021)

Reimbursement of pharmacogenetic tests at a tertiary academic medical center in the United States
por: Lemke, Lauren K., et al.
Publicado: (2023)

Stratified medicine in European Medicines Agency licensing: a systematic review of predictive biomarkers
por: Malottki, Kinga, et al.
Publicado: (2014)

Editorial: Role of Health Economic Data in Policy Making and Reimbursement of New Medical Technologies
por: Jakovljevic, Mihajlo, et al.
Publicado: (2017)

Reimbursed Medication Adherence Enhancing Interventions in European Countries: Results of the EUREcA Study
por: Ágh, Tamás, et al.
Publicado: (2022)

A Comparative Analysis of Pricing and Reimbursement of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Europe
por: Abdallah, Khadidja, et al.
Publicado: (2021)

Nursing Home Cost Studies and Reimbursement Issues
por: Bishop, Christine E.
Publicado: (1980)

Reimbursed medication adherence enhancing interventions in 12 european countries: Current state of the art and future challenges
por: Kardas, Przemysław, et al.
Publicado: (2022)

BEACON: A Summary Framework to Overcome Potential Reimbursement Hurdles
por: Dunlop, William C. N., et al.
Publicado: (2016)

Assessing the Value of Nusinersen for Spinal Muscular Atrophy: A Comparative Analysis of Reimbursement Submission and Appraisal in European Countries
por: Blonda, Alessandra, et al.
Publicado: (2022)

Health Economic Data in Reimbursement of New Medical Technologies: Importance of the Socio-Economic Burden as a Decision-Making Criterion
por: Iskrov, Georgi, et al.
Publicado: (2016)

Characteristics of drug safety alerts issued by the Spanish Medicines Agency
por: Montané, Eva, et al.
Publicado: (2023)

Medicines Compliance and Reimbursement Level in Portugal
por: Constantino Portela, Maria da Conceição, et al.
Publicado: (2015)

Clinical and economic impact of changing reimbursement criteria for statin treatment among patients with type 2 diabetes mellitus in South Korea
por: Kim, Siin, et al.
Publicado: (2022)

A human rights-based approach to the reimbursement of expensive medicines
por: Perehudoff, Katrina, et al.
Publicado: (2016)

The Budget Impact of Oral Nutritional Supplements for Disease Related Malnutrition in Elderly in the Community Setting
por: Freijer, Karen, et al.
Publicado: (2012)

Cost-effectiveness of prucalopride in the treatment of chronic constipation in the Netherlands
por: Nuijten, Mark J. C., et al.
Publicado: (2015)

Nutrition economic evaluation of a probiotic in the prevention of antibiotic-associated diarrhea
por: Lenoir-Wijnkoop, Irene, et al.
Publicado: (2014)

How Can We Optimize the Value Assessment and Appraisal of Orphan Drugs for Reimbursement Purposes? A Qualitative Interview Study Across European Countries
por: Blonda, Alessandra, et al.
Publicado: (2022)

An Ethnopharmaceutical Study on the Hypolipidemic Formulae in Taiwan Issued by Traditional Chinese Medicine Pharmacies
por: Chi, Min-Han, et al.
Publicado: (2022)

A Review of the Evidence on Attitudes, Perceived Impacts and Motivational Factors for European Member State Collaboration for Pricing and Reimbursement of Medicines: Time for the EEA Member States to Apply Their Experience and Expertise in Evidence-Based Decision Making to Their Current Pharmaceutical Policy Challenges
por: Vella Bonanno, Patricia, et al.
Publicado: (2021)

Efficacy of Resveratrol in Experimental Subarachnoid Hemorrhage Animal Models: A Stratified Meta-Analysis
por: Tan, Jiahe, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bm9tnh645rcc0u5s96g2itibg8